Our studies have documented for the first time that FD268, a pyridinesulfonamide derivative characterized by conjugation of 7-azaindole motif, possesses significant anti-leukemic activity towards AML cell lines by inhibition of PI3K/Akt/mTOR signaling pathway, thus supporting further development of pyridinesulfonamide derivatives as PI3K inhibitors for pre-clinical evaluation in treatment of AML. This evidence concerns the gene AKT1 and acute myeloid leukemia.